

**Announcement
21 July 2014****Coloplast – transactions in connection with share buy-back programme**

As mentioned in Announcement No. 2/2014 Coloplast is initiating the first part of the share buy-back programme totalling up to DKK 1bn. This part of the programme of DKK500m is expected to take place from 3 March, 2014 to 31 August, 2014 at the latest. The second part of the programme, of also DKK 500m, is executed in the 2014/15 fiscal year.

The following transactions have been executed during the period 14 – 18 July 2014:

Date	Number of shares	Average buying price	Amount DKK
14 July 2014	5,000	477.0000	2,385,000
15 July 2014	5,000	471.9000	2,359,500
16 July 2014	1,000	477.0000	477,000
17 July 2014	1,000	482.0000	482,000
18 July 2014	4,000	482.7000	1,930,800
Accumulated until now under the programme	945,000	455.5899	430,532,500

Henceforth, Coloplast owns 9,339,187 own B shares of DKK 1 equal to 4.25 % of the company's total share capital.

The second part of the programme, of also DKK 500m, is expected to take place from 1 October, 2014 to 30 September, 2015.

For further information, please contact

Investors and analysts

Ian S.E. Christensen
Vice President, Investor Relations
Tel. +45 4911 1800/+45 4911 1301
Email: dkisec@coloplast.com

Nick Fridberg
Sr. Investor Relations Manager
Tel. +45 4911 1800/+45 4911 1456
Email: dknf@coloplast.com

Press and the media

Simon Mehl Augustesen
Media Relations Manager
Tel. +45 4911 3488
Email: dksia@coloplast.com

This announcement is available in a Danish and an English-language version.
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2014-07 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ more than 8,500 people.